Warner Chilcott Beats Analyst Estimates on EPS
Warner Chilcott (NAS: WCRX) reported earnings on Feb. 24. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Warner Chilcott met expectations on revenues and beat expectations on earnings per share.
Compared with the prior-year quarter, revenue dropped and GAAP earnings per share grew significantly.
Margins improved across the board.
Warner Chilcott logged revenue of $645.8 million. The 15 analysts polled by S&P Capital IQ predicted revenue of $654.0 million on the same basis. GAAP reported sales were 7.0% lower than the prior-year quarter's $694.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.95. The 20 earnings estimates compiled by S&P Capital IQ predicted $0.90 per share on the same basis. GAAP EPS of $0.36 for Q4 were 500% higher than the prior-year quarter's $0.06 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 88.3%, 50 basis points better than the prior-year quarter. Operating margin was 28.5%, 1,250 basis points better than the prior-year quarter. Net margin was 14.0%, 1,180 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $645.1 million. On the bottom line, the average EPS estimate is $0.91.
Next year's average estimate for revenue is $2.57 billion. The average EPS estimate is $3.63.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 144 members out of 169 rating the stock outperform, and 25 members rating it underperform. Among 54 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give Warner Chilcott a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Warner Chilcott is outperform, with an average price target of $24.64.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Warner Chilcott the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.
- Add Warner Chilcott to My Watchlist.
At the time this article was published
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.